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Background and purpose — Tenosynovial giant cell tumors 
(t-GCTs) can behave aggressively locally and affect joint func-
tion and quality of life. The role of arthroplasty in the treatment 
of t-GCT is uncertain. We report the results of arthroplasty in 
t-GCT patients.
Patients and methods — t-GCT patients (12 knee, 5 hip) 
received an arthroplasty between 1985 and 2015. Indication for 
arthroplasty, recurrences, complications, quality of life, and func-
tional scores were evaluated after a mean follow-up time of 5.5 
(0.2–15) years.
Results — 2 patients had recurrent disease. 2 other patients 
had implant loosening. Functional scores showed poor results in 
almost half of the knee patients. 4 of the hip patients scored excel-
lent and 1 scored fair. Quality of life was reduced in 1 or more 
subscales for 2 hip patients and for 5 knee patients.
Interpretation — In t-GCT patients with extensive disease 
or osteoarthritis, joint arthroplasty is an additional treatment 
option. However, recurrences, implant loosening, and other com-
plications do occur, even after several years.
■
Tenosynovial giant cell tumors (t-GCTs) are benign prolif-
erative growths of the synovial membrane (de saint Aubain 
Somerhausen and van de Rijn 2013). The approximate annual 
incidence in the USA is 1.8 patients per million inhabitants 
(Verspoor et al. 2013). T-GCT mainly affects adults between 
20 and 50 years of age, with the same prevalence in both 
sexes. There is a predilection for weight-bearing extremities, 
the knee and the hip being the most commonly involved (Ver-
spoor et al. 2014).
The clinical presentation is non-specifi c, with mild discom-
fort, stiffness, effusion, or progressive pain. Based on the clin-
ical and radiological presentation, 2 subtypes of t-GCT  have 
been identifi ed, localized t-GCT (Lt-GCT) and diffuse t-GCT 
(Dt-GCT) (Murphey et al. 2008, Verspoor et al. 2014).
Treatment strategies are based on removal of all pathologi-
cal tissue. In primary, limited disease, a surgical synovectomy 
is often suffi cient (Verspoor et al. 2013). However, for exten-
sive or recurrent disease, complete surgical synovectomy can 
be a technical challenge. Recurrence rates have been reported 
to be between 0% and 15% for Lt-GCT and between 9% and 
46% for Dt-GCT, depending on the duration of follow-up and 
on the joint involved (Chiari et al. 2006, Dines et al. 2007, 
Verspoor et al. 2014).
A variety of treatment modalities in addition to surgical 
resection of t-GCT have been used to achieve cure, such as 
external beam radiation therapy, radiation synovectomy, cryo-
surgery, immune or targeted therapy, and joint arthroplasty. 
However, little is known about the actual effect of these addi-
tional treatments (Verspoor et al. 2013).
The surgical removal of t-GCT combined with arthroplasty 
has been described previously in patients with extensive dis-
ease, and in patients with destructive joint changes caused 
by the disease itself or by the multiple treatments patients 
received (Hamlin et al. 1998). The goal of this treatment is to 
achieve a disease-free, well-functioning joint (Flandry et al. 
1989). In addition, patients with osteoarthritis-like symptoms 
in whom t-GCT was an incidental fi nding during arthroplasty 
have been described (Della Valle et al. 2001).
This retrospective study was conducted to analyze the 
results of arthroplasty in patients with t-GCT. More specifi -
cally, we examined the indications, number of recurrences, 
complications, quality of life, and joint function in relation to 
t-GCT subtype and the joint affected. 
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Patients and methods
For this retrospective study, we identifi ed 141 t-GCT patients in 
our patient databases (1985–2015). 48 patients were classifi ed 
as Lt-GCT and 93 as Dt-GCT. 17 of these patients (5 Lt-GCT 
and 12 Dt-GCT) received an arthroplasty (Tables 1 and 2).
Clinical, pathological, radiological, treatment, and follow-
up information were assessed by 2 independent reviewers 
(FGMV and AS). Any disagreements were resolved by con-
sensus with a third reviewer (HWBS). Recurrences, treatment 
complications, functional scores, and quality of life (QoL) 
were documented according to t-GCT subtype and location. 
During the regular hospital visits, QoL questionnaires were 
used and function scores were taken.
QoL was evaluated by using the Dutch translation of a 
generic QoL instrument, the 36-item Short Form health survey 
(SF-36) (VanderZee et al. 1996) and the 20-item Checklist 
Individual Strength (CIS20r) questionnaire (Vercoulen et al. 
1999). 14 patients participated, and the other 3 patients were 
lost to follow-up. 1 patient did not complete all the questions 
in the CIS20r questionnaire, so it could not be used.
Scoring systems used to evaluate function were the stan-
dardized Western Ontario and McMaster Universities osteo-
arthritis index (WOMAC) (Bellamy et al. 1988), the Knee 
Society score (KSS) (Insall 1988), and the Harris hip score 
(HHS) (Garellick et al. 1998). The data were extracted from 
database records. We managed to collect function scores from 
all but 1 patient.
Ethics
The study protocol (2012/555) was assessed by our institu-
tional review board (the research ethics committee of the Rad-
boud University Nijmegen Medical Centre) and was carried 
out in the Netherlands in accordance with the applicable rules 
concerning the review of research ethics committees.
Results
Hip
5 patients received a hip arthroplasty. 4 had Dt-GCT and 1 
had Lt-GCT. 2 were women aged 20 and 25 years and 3 were 
men aged 36, 44, and 49 years. The indication for total hip 
arthroplasty (THA) was extensive disease (n = 3) and second-
ary osteoarthritis (n = 1). In the fi fth patient, Lt-GCT was an 
incidental fi nding. The mean overall follow-up after arthro-
plasty was 8.6 (7–15) years (Table 1).
3 primary patients received their arthroplasty within 1.5 
years of diagnosis (Table 1). 1 patient with recurrent disease 
had a surgical synovectomy followed by an unsuccessful 
yttrium radiosynovectomy elsewhere. 4 years after diagnosis, 
this patient was treated at our tertiary center using a 3-stage 
Table 1. Details of t-GCT patients treated with arthroplasty: demographics, indications, recurrences, and length of follow-up a
     FU (in years)  No. of    FU (in years) Recurrence(s)
  Age at Type of  prior to previous Indication for Age at  after after
ID Gender diagnosis t-GCT Side arthroplasty recurrence(s) arthroplasty arthroplasty Implant b arthroplasty arthroplasty
Knee
 5 F 55 Diffuse L   7.5 4 Extensive disease 62 TKA 5.9 1 c
 7 F 41 Localized L   6.8 0 Osteoarthritis 48 TKA 3.3 0
 22 F 61 Localized L   0 0 Incidental 61 PF 8.3 0
 32 F 44 Diffuse R   8.4 2 Extensive disease 52 TKA 0.2 0
 40 M 38 Diffuse L 17.4 2 Extensive disease 56 TKA 3.5 0
 44 F 60 Diffuse L 1.6 0 Extensive disease 62 TKA 5.3 0
 56 F 47 Diffuse R 16.2 1 Extensive disease 63 TKA 5.4 0
 69 M 62 Localized R   0 0 Incidental 62 TKA 12.9 0
 75 M 28 Diffuse R   8.1 1 Osteoarthritis 36 PF 10.8 0
 105 M 73 Localized L   0 0 Incidental 73 HP 6.3 0
 120 M 24 Diffuse R 37.9 1 Osteoarthritis 62 TKA 2.3 0
 132 M 30 Diffuse R   3.2 3 Extensive disease 33 TKA 2.1 0
Hip
 1 M 44 Diffuse R   0.5 1 Extensive disease 44 THA 10.7 1 d
 3 M 34 Diffuse R   1.5 1 Extensive disease 36 THA 8.4 0
 34 V 24 Diffuse R   0.7 1 Osteoarthritis 25 THA 7.0 0
 92 M 49 Localized R   0 0 Incidental 49 THA 10.7 0
 115 V 16 Diffuse R   4.3 2 Extensive disease 20 THA 14.6 0
a The follow-up prior to arthroplasty was defi ned as the period between fi rst pathological conformation of diagnosis and arthroplasty. 
The follow-up after arthroplasty was defi ned as the period between arthroplasty and the most recent patient contact. Time to recurrence after 
arthroplasty was calculated as the time from joint arthroplasty until histologically proven recurrent disease, or highly suspected recurrent dis-
ease on ultrasound.
b TKA: total knee arthroplasty; PF: patellofemoral arthroplasty; HP: hemiarthroplasty of knee; THA: total hip arthroplasty. 
c On ultrasound.
d Histologically confi rmed
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procedure. During almost 15 years of follow-up, no recur-
rences or complications occurred (Tables 1 and 2).
Another patient who was initially treated using a 3-stage 
procedure for extensive disease (Table 2) fi rst had an anterior 
luxation immediately after THA with acetabular bone impac-
tion grafting, followed by a cup revision after a trauma 5 years 
later (without any evidence of recurrent disease), and fi nally 
had histologically proven recurrent disease 4 years after that. 
This recurrent disease was treated with a synovectomy, addi-
tional cryosurgery, and removal of osteosynthesis material 
that had been placed during the initial THA (Table 2).
Quality of life
An SF-36 score was obtained for 4 of the 5 patients, on aver-
age 10 (6–15) years after arthroplasty. 2 patients scored low (> 
1 SD below the means for the general population (VanderZee 
et al. 1996)) on Vitality and General health perception and 1 
of these 2 patients also scored low on Physical functioning, 
Social functioning, Role limitations due to physical problems, 
General mental health, and Bodily pain (Table 3, see Supple-
mentary data).
CIS20r was obtained for 4 patients, on average 10 (6–15) 
years after arthroplasty. Compared to healthy individuals 
Table 2. All the treatments t-GCT patients received before and after arthroplasty, including complications and implant information
  Treatments b 
ID Center a First  Second Third Fourth Fifth Type of implant
Knee
 5 R SE c + ME SE 2-stage SE + Cryo + RT TKA PS + PC, cemented g  
 7 P Nodulectomy Arthrotomy x Arthroscopy x TKA d, x MUA x PS, cemented g
 22 P Patella fracture      PF, cemented j
   –> osteosynthesis PF i     
 32 P 2-stage SE SE +TKA neurolysis x  PS + PC, cemented g
 40 R SE SE 2-stage + Cryo + TKA   PS, cemented g
 44 P SE + TKA d MUA x Revision tibia x   CR, cemented g, h 
 56 P SE SE + TKA    PS + PC, cemented g
 69 R TKA i     CR + PC, cemented k  
 75 R Yttrium 2-stage PF x   PF, cemented j
 105 R TKA i     HP, cemented l 
 120 P SE Yttrium TKA x    PS + PC, cemented g
 132 R SE SE SE + Yttrium Imatinib,  SE + TKA PS + PC, cemented m
      no response 
Hip
 1 P 3-stage + Cryo +  Cup revision x,f SE + Cryo   THA, BIG, cemented n
   THA e with  OSM removal    mesh, Kreutzschale 
   acetabular BIG     
 3 R SE with luxation THA    THA, cemented n
 34 P SE THA x    THA, BIG, cemented n
 92 R THA f     THA, cemented n
 115 R SE Yttrium 3-stage + Cryo + THA   THA, uncemented o 
a Center: Primary patients (P) underwent all treatments at our institution; referred patients (R) had their initial treatment(s) elsewhere. 
b Treatments:
SE: surgical synovectomy; ME: partial meniscectomy; OSM: osteosynthesis material; TKA: total knee arthroplasty (i incidental fi nding); 
PF: patellofemoral arthroplasty; HP: hemi knee arthroplasty; THA: total hip arthroplasty, 
2-stage = an anterior synovectomy followed by a posterior synovectomy 4-6 weeks later, 
3-stage = a complete synovectomy followed by a second look with excision of residual disease and arthroplasty in a third procedure; 
Cryo: additional cryosurgery peroperatively; BIG: bone impaction grafting; Yttrium: radiosynovectomy with yttrium; 
MUA: manipulation of the knee under anesthesia; RT: external beam radiation therapy; PS: posterior stabilized; 
PC: patellar component; CR: cruciate retaining.
x treatment not for recurrent disease.
Perioperative complications included: 
c delayed wound healing, 
d stiffness, 
e hip dislocation, 
f traumatic cup displacement.
Implants:
g PFC SIGMA TC3 - DePuy Synthes
h
 with extended stem tibia (3 cm)
j Smith & Nephew patellofemoral prosthesis model III long femoral
k PFC Genesis II - DePuy Synthes
l Oxford – Biomet
 m Nexgen - Zimmer
n Exeter stem + Contemporary cup – Stryker
o Link screw in cup + MP reconstruction prosthesis
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(Vercoulen et al. 1999), 1 patient scored high (> 1 SD above 
healthy individual means) on all 4 domains: Fatigue, Concen-
tration, Motivation, and Physical activity (Table 4, see Supple-
mentary data).
Function scores
A Harris hip score was obtained for all 5 THA patients, on 
average 6.8 (4–13) years after arthroplasty. 4 patients scored 
excellent (90–99) and 1 patient scored fair (77) (Table 5, see 
Supplementary data).
Knee
12 patients, 4 with Lt-GCT and 8 with Dt-GCT, received a 
knee arthroplasty, 6 women (mean age 58 (48–63) years) and 
6 men (mean age 54 (33–73) years). Indications for arthro-
plasty were extensive disease (n = 6), secondary osteoarthritis 
(n = 3), and an incidental fi nding (n = 3) (Tables 1 and 2). 
The mean overall follow-up period after arthroplasty was 5.5 
(0.2–13) years (Table 1).
Patient 7 (Lt-GCT) received a total knee arthroplasty (TKA) 
for osteoarthritis almost 7 years after diagnosis of t-GCT. 
Rehabilitation was complicated by stiffness, which was treated 
by manipulation under anesthesia. 2 other patients with osteo-
arthritis received a TKA, 8 and 38 years after diagnosis of 
Dt-GCT.
The 6 patients who were treated for extensive disease 
received an arthroplasty on average 9 (1.6–17) years after 
diagnosis (Table 1). These patients had 0–4 recurrences before 
arthroplasty and 1 recurrence diagnosed by ultrasound after 
TKA with so far no intervention. 2 patients suffered postoper-
ative complications after TKA. 1 patient had neuropathic pain, 
which was treated with surgical neurolysis (Figure 1). Another 
patient experienced stiffness, which was treated by manipula-
tion under anesthesia. This last patient also developed medial 
tibial component loosening 6 years after arthroplasty, fol-
lowed by revision surgery. No recurrent disease, polyethylene 
wear, or infection was found.
Quality of life
SF-36 was obtained for 10 patients, on average 4.6 (0.2–11) 
years after arthroplasty. 5 patients scored low (> 1 SD below 
the means for the general population) on General health per-
ception; 4 on Physical functioning, Role limitations due to 
physical problems, Vitality, and Health change; 3 on Social 
functioning, General mental health, and Bodily pain; and 2 
on Role limitations due to emotional problems (Table 3, see 
Supplementary data).
CIS20r was obtained for 9 of the patients, on average 4.6 
(0.2–11) years after arthroplasty. Compared to healthy indi-
viduals (Vercoulen et al. 1999), 2 patients scored high (> 1 SD 
above the means for healthy individuals) in all 4 domains, i.e. 
Fatigue, Concentration, Motivation, and Physical activity, and 
1 patient scored high on the Motivation and Physical domains 
(Table 4, see Supplementary data).
Function scores
WOMAC (Bellamy et al. 1988) and KSS (Insall 1988) were 
obtained for all but 1 patient, at an average of 3.7 (0.2–11) years 
after arthroplasty. According to the standardized WOMAC 
sum scores (0–100), higher values indicate less pain, less stiff-
ness, or better physical functioning (Roorda et al. 2004). 2 
knee patients scored below 50 on all subscales. 3 other knee 
patients had less than 70 in the total score; in particular, they 
had low scores on the Stiffness and Physical functioning sub-
scales. On the KSS Object knee score, 7 patients had excellent 
results (80–100), 1 had good results (70–79), and 3 had poor 
results (< 60). On the KSS Function knee score, 6 patients 
had excellent results (80–100) and the other 5 patients had 
poor results (< 60), as with the low WOMAC scores in these 5 
patients (Table 6, see Supplementary data).
Discussion
Indications
In this study, t-GCT patients with extensive disease and/or 
degenerative joint disease following treatment(s) were eligible 
for arthroplasty. Also, there were patients who were preop-
eratively assumed to have osteoarthritis which (during opera-
tion) turned out to be t-GCT. Other authors have found similar 
indications for arthroplasty in t-GCT patients (Bunting et al. 
2007, Lawrence et al. 1999, Murphey et al. 2008). Further-
more, unusual cases of t-GCT fi rst presenting after TKA have 
been described (Bunting et al. 2007, Ma et al. 2013).
Figure 1. Gradient-echo-based MRI image from a patient with recurrent 
t-GCT (right knee). There was very low signal intensity corresponding 
to hemosiderin depositions anterior to the lateral meniscus, extend-
ing to the infrapatellar fat pad. Furthermore, there was a hemosiderin 
deposition in the recessus lateralis posterior to the lateral femoral 
condyle. These localizations corresponded to recurrent Dt-GCT, which 
was confi rmed by surgical removal.
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In general, patients with t-GCT in the hip received their 
arthroplasty over 20 years earlier than patients with t-GCT 
of the knee. An explanation for this age difference might be 
that lesions involving the hip joint are associated with a higher 
incidence of bony erosion and cyst formation compared to 
those involving the knee. Some investigators have hypothe-
sized that the smaller intra-articular space in the hip does not 
allow the tumor to expand without causing increased pressure 
on the femoral and acetabular cartilage (Verspoor et al. 2013).
THA has been performed in young patients, with good 
results. However, the authors of a long-term follow-up evalu-
ation of THA advised caution with this procedure in younger 
patients because of high failure rates (de Kam et al. 2011). 
Recurrences
2 recurrences were found in our patient group; both of these 
Dt-GCT patients were treated for extensive disease. The recur-
rence after THA was histologically proven. The recurrence 
after knee arthroplasty was diagnosed and followed on ultra-
sound. There have been case reports of recurrent t-GCT being 
diagnosed with arthroscopy or during revision arthroplasty 
(Ma et al. 2011). However, with the improved visualization 
of periprosthetic soft tissues on MRI, diagnosis of recurrent 
t-GCT after total joint arthroplasty should no longer be a dif-
fi culty (Friedman et al. 2013).
Gitelis et al. (1989) reported on 28 patients in whom syno-
vectomy was combined with hip arthroplasty (15 cup arthro-
plasties, 10 THAs, and 3 hemiarthroplasties—1 of which was 
subsequently converted to a THA). The average follow-up 
time was 3.6 years, with 1 recurrence.
In our study, the 2 recurrences occurred 6 and 9 years after 
arthroplasty, indicating that the number of recurrences may 
increase further with longer follow-up times. These 2 patients 
with recurrent disease had a staged procedure before arthro-
plasty. In hip arthroplasty, clearance of diseased tissue was 
done before implantation, to minimize the chance of recurrent 
disease. However, 1 of the 2 hip patients who underwent a 
staged procedure showed recurrent disease. A meta-analysis 
of t-GCT in hips showed a recurrence rate of 4% with surgi-
cal synovectomy and total joint arthroplasty as compared to 
a rate of 28–50% after treatment with surgical synovectomy 
alone. The indication for additional arthroplasty depended on 
the extent of disease and on cartilage damage (Della Valle et 
al. 2001).
With extensive Dt-GCT, extra-articular lesions are often 
encountered, e.g. in the head of one of the gastrocnemius 
muscles (Figure 2). In these cases, all pathological tissue 
should be removed before joint arthroplasty, to reduce the risk 
of residual and/or recurrent disease. To ensure removal of all 
pathological tissue, before arthroplasty a staged procedure 
should be considered in these diffi cult-to-cure patients.
Complications
We had 2 cases of aseptic loosening 5 and 6 years after 
arthroplasty, but not recurrent disease. Hamlin et al. (1998) 
described 18 patients who underwent TKA, 14 with Dt-GCT 
and 4 with Lt-GCT. There were 3 cases of aseptic loosening, 1 
of them with recurrent disease. Another patient with recurrent 
disease needed an above-the-knee amputation. 
Other complications, such as stiffness requiring manipu-
lation and neuropathic pain requiring neurolysis, have been 
reported in patients undergoing arthroplasty (Healy et al. 
2013). However, this patient group is possibly more prone to 
develop these kinds of complications from limited joint func-
tion preoperatively, due to the disease itself or to previously 
received treatments (Verspoor et al. 2014).
Quality of life
In 5 patients, we found reduced QoL scores compared to the 
general population (VanderZee et al. 1996). Recently, 2 other 
publications had QoL scores for t-GCT patients (van der Hei-
jden et al. 2014, Verspoor et al. 2014) but these scores were 
not reported for t-GCT patients treated with arthroplasty.
Joint function
We found reduced joint function after arthroplasty in 5 of 
the 12 t-GCT knee patients, mainly due to stiffness (Table 6, 
see Supplementary data). It has been reported that preopera-
tive joint function is a predictor of postoperative TKA func-
tion (Jones et al. 2003). In general, reduced preoperative joint 
function in t-GCT patients is related to disease severity or the 
often multiple treatments in the past (Chiari et al. 2006). Simi-
lar results have been reported for postoperative hip function 
(Fortina et al. 2005). However, 4 out of 5 of our hip arthro-
plasty patients had excellent Harris hip scores. Gitelis et al. 
Figure 2. Gradient-echo-based MRI image from a patient with recurrent 
t-GCT (left knee). There was very low signal intensity corresponding to 
hemosiderin depositions, particularly in the posterior compartment of 
the joint and in the popliteal fossa. There was also osseous destruction.
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(1989) reported that after an average follow-up of 5 years, 24 
of 28 patients treated with primary hip arthroplasty had satis-
factory results and 4 had poor results. The poor results were 
due to mechanical failure of the implants (Gitelis et al. 1989).
Our hip arthroplasty patients had better function scores than 
our knee patients, which might be explained by their younger 
age and shorter course of disease. Taking disease-induced loss 
of joint function into consideration, joint function outcomes 
may be better with earlier joint arthroplasty. It may also reduce 
the chances of recurrent t-GCT, as the disease is less extensive 
and therefore easier to eradicate. However, early joint arthro-
plasty might result in higher revision rates.
Limitations
The retrospective character of this study, the small number of 
patients, the different indications for arthroplasty, and the dif-
ferent implants used should not go unnoticed. It is diffi cult to 
perform a prospective study with adequate patient numbers, 
because of the low incidence of t-GCT and the years of delay 
before local recurrence may occur. Complete information 
regarding subtypes, location, arthroplasty, and other treat-
ments was available, including long-term follow-up. Because 
of this, the information could possibly be used in future 
(meta-)analyses to obtain evidence regarding arthroplasty in 
the treatment of t-GCT. Furthermore, patients with localized 
t-GCT as an incidental fi nding should be differentiated from 
those with diffuse recurrent and extensive t-GCT, as localized 
disease behaves less aggressively.
It should also be noticed that QoL and function scores were 
taken at variable points after arthroplasty. To our knowledge, 
this is the fi rst study to report QoL measures in t-GCT patients 
who underwent arthroplasty. QoL is important in a disease as 
disabling as t-GCT. Further studies should investigate whether 
or not the reduced QoL in this specifi c patient group is a con-
sequence of the disease itself, of the arthroplasty, of the (mul-
tiple) treatment(s) received, or of other factors, such as comor-
bidities or issues not related to disease. 
In summary, in t-GCT patients with extensive disease or 
osteoarthritis, arthroplasty is an additional treatment option 
after surgical synovectomy. However, recurrences, implant 
loosening, and other complications do occur, even after years 
of follow-up.
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